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Abstract: Recent advancement in mass spectrometry leads us to a new era of proteomic analysis. Human saliva can be 
easily collected; however, the complexity of the salivary proteome in the past prevented the use of saliva for proteomic 
analysis. Here we review the development of proteomic analyses for human saliva and focus on the use of a new mass 
spectrometric technology known as surface-enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF). SELDI-TOF, a modification of matrix-assisted laser desorption/ionization mass spectrometry (MALDI-
TOF), combines the precision of mass spectrometry and the high-through-put nature of protein arrays known as Protein 
Chips. This technology shows a promising future for salivary proteomic analysis in monitoring treatments and diseases, as 
well as novel biomarker discovery. 
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INTRODUCTION  
  Proteomic analysis involves the study of complex mix-
tures of proteins and their interactions. The term proteome 
dates back to 1994 when Marc Wilkins defined it as “the 
total protein content of a genome” [1, 2]. Proteomic analysis 
can be viewed as an experimental approach to explain the 
information contained in genomic sequences in terms of the 
structure, function, and control of biological processes and 
pathways. Therefore, the proteome reflects the cellular state 
or the external conditions encountered by a cell. In addition, 
proteomic analysis can be viewed as a genome-wide assay to 
differentiate distinct cellular states and to determine the mo-
lecular mechanisms that control them
 [3]. It is now generally 
recognized that expression analysis directly at the protein 
level as well as chemical modifications of expressed proteins 
are necessary to unravel the critical changes that occur as 
part of disease pathogenesis [4]. 
  Quantitative proteomic analyses can be used to identify 
the protein content in complex samples such as cell and tis-
sue extracts or subcellular fractions, and to determine the 
quantitative difference in abundance for each polypeptide 
contained in different samples. It is expected that the pro-
teomic profiling patterns resulting from such analyses define 
comprehensive molecular signatures in health and disease. 
Analyses of the proteomic profiles would impact a wide 
range of biological and clinical research questions, such as  
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the systematic study of biological processes and the discov-
ery of clinical biomarkers for detection, diagnosis, and as-
sessment of treatment outcome. The exploitation of a pro-
teomic approach for the study of different diseases has led to 
the hypothesis that multiple biomarkers or a panel of bio-
markers shown by proteomic profiling may correlate more 
reliably with a specific disease than a single biomarker or 
protein [4-6].  
  Biomarkers can be defined as cellular, biochemical, and 
molecular alterations by which normal, abnormal, or simply 
biologic processes can be recognized or monitored. These 
alterations should be able to objectively measure and evalu-
ate normal biological process, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention. 
Therefore, proteomic profiling is valuable in the discovery of 
biomarkers as the proteome reflects both the intrinsic genetic 
program of the cell and the impact of its immediate envi-
ronment. Protein expression and function are subject to 
modulation through transcription as well as through transla-
tional and posttranslational events. In addition, biomarkers 
can be subtle changes in molecular structures, for instance 
alterations of post-translation modifications, which often can 
only be examined at the protein level [1-6]. 
  Currently investigators are pursuing three different ap-
proaches to develop a technology to study biomarkers with 
increased sensitivity and specificity. The first is to improve 
on currently used or known biomarkers. The second ap-
proach is to discover and validate novel biomarkers with 
greater sensitivity and specificity. The third approach is to 
use a panel of biomarkers, either by combining several indi- 
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vidually identified biomarkers or by using mass spectrome-
try to identify a pattern of protein peaks in sera that can be 
used to predict the presence of cancer or other diseases. Ex-
pression pattern of a known biomarker or correlation of ex-
pression of several known biomarkers can be a valuable re-
search and clinical tool for monitoring disease or treatment 
progression. High-throughput proteomic methodologies have 
the potential to revolutionize protein biomarker discovery 
and to allow for multiple markers to be assayed simultane-
ously. With the significant advances in mass spectrometry 
and proteomics technologies, protein biomarker discovery 
has become one of the central applications of proteomics [4-
6]. 
BIOMARKER DISCOVERY IN HUMAN SALIVA 
  One might think tissue biopsy is the ideal specimen for 
disease biomarker study. However, in terms of disease diag-
nosis and prognosis, a human body fluid (e.g., blood, urine, 
or saliva) appears to be more attractive because body fluid 
testing provides several key advantages including low inva-
siveness, minimum cost, and easy sample collection and 
processing. Analysis of body fluid is inherently challenging 
because it contains a large number of proteins that could be 
modified in a variety of forms. Due to its complexity, a 
number of variables need to be considered, including sample 
preparation and handling, protein prefractionation, affinity 
depletion of highly abundant proteins, isolation of subpro-
teomes (e.g., glycoproteome and phosphoproteome), multi-
dimensional chromatographic separation, quantification of 
proteins, data analysis, database search criteria, etc. [1, 3, 5-8]. 
  Human plasma proteins originate from a variety of tissue 
and blood cells as a result of secretion or leakage. An issue 
with serum samples is sample preparation and handling. An-
other critical point is the complexity of the proteome [7,8]. 
Plasma/serum contains a huge number of proteins differing 
by the extraordinary dynamic range of at least 9-10 orders of 
magnitude. Many of these proteins are glycosylated or bound 
to other carrier proteins [7]. How to globally quantify the 
proteins in free, bound, or modified forms remains a critical 
challenge. In this regard the next logical step is to take serum 
screening one step further by discovering and utilizing mul-
tiple biomarkers, consisting of a pattern of upregulated 
and/or downregulated protein. In terms of early detection of 
disease progression or response to treatments, alteration of 
particular biomarker expression patterns may be indicated 
before the onset of symptoms [9]. 
  Recently human saliva became a more attractive source 
for proteomic profiling. The human salivary glands produce 
almost 600 mL/day of serous and mucinous saliva containing 
minerals, electrolytes, buffers, enzymes and enzyme inhibi-
tors, growth factors and cytokines, immunoglobulins (e.g., 
secretory immunoglobulin A [sIgA]), mucins and other gly-
coproteins [10-12]. Saliva plays two main roles in the bio-
logical function of the oral cavity: it is essential for the mas-
tication, swallowing and digestion processes, and protects 
the teeth and the mucosal surface by means of lysozymes, 
cystatins, immunoglobulins and histatins which prevent the 
growth of microrganisms in the oral cavity [10]. In addition, 
the multifarious components within saliva not only protect 
the integrity of the oral tissues, but also provide clues to lo-
cal and systemic diseases and conditions. These “salivary 
biomarkers” are being explored as a means of monitoring 
general health and in the early diagnosis of disease [11, 12]. 
Indeed, human saliva has been examined in the search for 
biological markers of multiple systemic diseases, such as 
cancer, HIV, Sjgren’s syndrome and cystic fibrosis [10-12]. 
  In the past, serum has been the fluid most often used in 
disease diagnosis; however, saliva is a useful medium for 
disease diagnosis and has many advantages over both serum 
and urine [7,8, 10-12]. For example, salivary assays for anti-
bodies (to viruses and bacteria), unconjugated steroid hor-
mones (e.g., estrogen, testosterone and progesterone), envi-
ronmental toxins (e.g., cadmium, lead and mercury), tobacco 
(nicotine) and certain drugs (e.g., ethanol, theophylline and 
lithium) are sufficiently sensitive to accurately reflect the 
blood concentrations of these substances [11,12]. In the 
clinic or the laboratory, saliva is relatively easy to collect in 
sufficient quantities for analysis, and the costs of storage and 
shipping tend to be lower than those for serum and urine. 
Noninvasiveness, and ease of sample processing are advan-
tageous as well [7,8, 10-12]. In addition, for health care pro-
fessionals and scientists, saliva tests are safer than blood 
tests, which are more likely to result in exposure to HIV or 
hepatitis [7]. On the other hand, a variety of factors may in-
fluence the rate of salivary flow and its physiologic charac-
teristics, including circadian rhythms and activities such as 
exercise, and these factors should be taken into account 
when saliva is used as a diagnostic fluid [10-12]. 
  Protein arrays, such as Protein Chips, are solid-phase 
ligand-binding assay systems using immobilized proteins on 
surfaces such as glass, cellulose membranes, mass spec-
trometer plates, microbeads, or micro/nanoparticles. The 
main advantages of protein arrays include high-throughput, 
exquisite sensitivity, and minute sample required for analysis 
[10]. However, the expression and purification of capture 
proteins, especially antibodies, is cumbersome. The design 
of capture arrays, particularly when screening against com-
plex samples, also needs to take into consideration the prob-
lem of crossreactivity [7]. 
  Considering the relatively high co-existence rate for sa-
liva proteins and their counterpart mRNAs, the salivary tran-
scriptome derived from DNA microarray analyses may serve 
as a good indicator of the diversity and range of the salivary 
proteome, and can be used as a reference guideline for hu-
man saliva mass spectrometry proteomic profiling [12]. For 
example optical fiber microarrays have been used to screen 
saliva from patients with end-stage renal disease (ESRD) to 
ascertain the efficacy of dialysis, where two salivary analytes 
(nitrite and uric acid) were successfully identified markers in 
saliva that correlate with kidney disease that were elevated in 
predialysis patients and were shown to be reduced following 
dialysis [13]. 
  According to Hu et al. [12] a comparative analysis of the 
saliva proteome and transcriptome showed that many sali-
vary proteins and mRNA are concordantly present in human 
saliva when comparison is performed within the same indi-
vidual. Complementarity was obvious for common saliva 
proteins (such as statherin, histatins, cystatins, and proline-
rich proteins), saliva enzymes (such as lysozyme, amylase, 
lactate dehydrogenase, and cytochrome c oxidase), and struc-
tural proteins (such as actins, tubulins, and keratins) [12]. 76    The Open Dentistry Journal, 2009, Volume 3  Al-Tarawneh and Bencharit 
USE OF MASS SPECTROMETRY IN SALIVARY 
PROTEOMICS 
  Proteomic attempts to study biological processes com-
prehensively by the systematic analysis of the proteins ex-
pressed in a cell or tissue. Mass spectrometry is currently 
proteomic’s most important tool [14]. Mass spectrometry has 
been a powerful tool not only for protein identification in 
proteome analysis but also for the study of post-translational 
modifications of proteins, as well as chemical modification 
of proteins [1]. 
  By definition, a mass spectrometer consists of an ion 
source, a mass analyser that measures the mass-to-charge 
ratio (m/z) of the ionized analytes, and a detector that regis-
ters the number of ions at each m/z value. The mass analyser 
is, literally and figuratively, central to the technology [14]. 
There are four basic types of mass analyser currently used in 
proteomic research. These are the ion trap, time-of-flight 
(TOF), quadrupole and Fourier transform ion cyclotron ana-
lysers, and they are very different in design and performance, 
each with its own strength and weakness [14]. Mass spec-
trometric measurements are carried out in the gas phase on 
ionized analytes [1, 2, 14]. 
  During the decade of the 1990s, changes in mass spec-
trometric instrumentation and techniques revolutionized pro-
tein chemistry and fundamentally changed the analysis of 
proteins [1-5, 14]. These changes were catalyzed by two 
technical breakthroughs in the late 1980s: the development 
of the two ionization methods electrospray ionization (ESI) 
and matrix-assisted laser desorption/ionization (MALDI). 
The ease with which proteins and peptides could be ionized 
by these methods rapidly made mass spectrometry a com-
plementary technique to nuclear magnetic resonance (NMR), 
X-ray crystallography, circular dichroism (CD), and other 
classical methods of protein chemistry to study diverse as-
pects of protein structure and function [1, 2]. For example In 
order to develop an ELISA respective biomarker proteins 
have to be purified and specific antibodies must be (com-
mercially) available [9] and requires two antibodies for each 
protein that is being assayed [15] with high purity and high 
specificity. As a result, only a limited number of markers are 
currently applied for cancer detection for example. In con-
trast, mass spectrometry allows the multivariate analysis of 
complex patterns of new biomarkers without knowing their 
individual identities and without having specific monoclonal 
antibodies available. The proteins underlying individual 
peaks used for the differentiation do not have to be identified 
initially, although it may become necessary to determine the 
relation to the disease for a broad acceptance by the clini-
cians [9]. 
MATRIX-ASSISTED LASER DESORPTION/ION- 
IZATION (MALDI)  
  MALDI is an improvement of the laser desorption ioni-
zation (LDI) technique [1,3-6]. In LDI, a soluble analyte is 
air dried on a metal surface and the ionization is achieved by 
irradiating with an ultraviolet laser. The disadvantage of 
conventional LDI is that, in general, it has low sensitivity, 
the ionization method causes ion fragmentation, and the sig-
nal is very dependent on the ultra-violet absorbing character-
istics of the analyte. This is solved with MALDI by decoup- 
 
ling the energy needed for desorption and ionization of the 
analyte. In MALDI, the analyte is mixed with a compound, 
the matrix, which absorbs the energy from the laser. The 
sample is co-crystallized with an excess amount of the ma-
trix. A variety of matrices, small aromatic acids can be used. 
The aromatic group absorbs at the wavelength of the laser 
light, while the acid supports the ionization of the analyte. 
Irradiation with a short-pulsed laser, often a 337-nm N2 laser, 
causes mainly ionization of the matrix followed by energy 
and proton transfer to the analyte [1, 3-6]. 
  The main advantage with MALDI ionization is high sen-
sitivity [5-6]. Time-of-flight (TOF) mass analyzer most 
commonly used with MALDI is robust, simple, and sensitive 
and has a large mass range. MALDI-TOF mass spectra are 
simple to interpret due to the propensity of the method to 
generate predominantly singly charged ions [3-6]. However, 
one of the biggest problems with MALDI-TOF for identifi-
cation of proteins is the difficulty in obtaining highly signifi-
cant search result. This is owing to the fact that not all the 
expected tryptic peptides show up in the experimental MS 
spectrum [10]. Another problem related to the MALDI 
method is the heterogeneity in matrix-sample crystal forma-
tion, which makes it difficult to quantify and reproduce re-
sults [10]. Using fast evaporation methods when applying 
the matrix seem to give more homogenous matrix-sample 
crystals. However, it is still often necessary to search for a 
good sample spot with a target [6]. In addition, it is very time 
consuming, expensive, and the matrix preparation has a ma-
jor effect on the quality of MALDI-TOF spectra [10]. There 
is no universal matrix preparation procedure that gives good 
results for all peptides and proteins. Only general guidelines 
have been found, such as the requirement of the sample-
matrix mixture to be adjusted to pH less than 2.0 for optimal 
signal-to-noise ratio [5, 6]. 
SURFACE-ENHANCED LASER DESORPTION/ ION- 
IZATION (SELDI)  
  The original concept of surface-enhanced laser desorp-
tion/ ionization (SELDI) was perhaps first described in 1992 
by Hutchens and Yip [16-18]. Among the proteomic ap-
proaches, SELDI-TOF mass spectrometry is a high-
throughput technique, particularly appropriate for the inves-
tigation of low-molecular weight proteins (<20 kDa) with 
femtomole sensitivity and the ability to examine native pro-
teins [10, 16-18]. SELDI-TOF can be described as a type of 
MALDI-TOF mass spectrometry where the sample matrix, 
known as Protein Chip, has an active role in sample purifica-
tion as well as the desorption/ionization step [10, 18]. This 
technology is based on the separation of proteins using their 
chemical and physical characteristics (i.e., hydrophobic, hy-
drophilic, acidic, basic, metal affinity) by performing a 
chromatographic separation of the sample to be analyzed 
[19]. Three major components constitute SELDI-TOF: the 
Protein Chip arrays, the mass analyzer, and the data analysis 
software. The principle of this technique is very simple. A 
few microliters of a sample of interest are deposited on the 
chromatographic surface. The Protein Chip arrays are incu-
bated and then washed with an appropriate buffer. The pro-
teins of interest are captured on the chromatographic surface 
by adsorption, partition, electrostatic interaction or affinity 
chromatography depending on their properties, and analyzed  
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by TOF mass spectrometry. The result is a mass spectrum 
comprised of the mass to charge (m/z) values and intensities 
of the bound proteins/peptides [20]. Then, using these chro-
matographic surfaces, a laser desorption (LD) time-of-flight 
(TOF) mass spectrometer can generate an accurate protein 
profile of a biological sample requiring minimal amounts of 
sample. The protein sample may be analyzed directly or after 
proteolytic digestion of the adsorbed material [19]. Proteoly-
sis of a protein after desorption can be used to identify bind-
ing sites such as antibody epitope sites [1]. 
  While SELDI-TOF provides a unique sample preparation 
platform, it is similar to MALDI-TOF in that a laser is util-
ized for the ionization of samples that have been co-crystall- 
ized with a matrix on a target surface. Unlike MALDI-TOF 
target surfaces, however, the SELDI-TOF Protein Chip sur-
faces are uniquely designed to retain proteins from complex 
mixtures according to their specific properties using chroma-
tographic-based selectivity [20]. 
  One of the unique strengths of SELDI-TOF is its ability 
to analyze proteins from a variety of crude sample types, 
with minimal sample consumption and processing [20]. 
SELDI-TOF is very rapid and it can directly test native un-
digested biological samples. The use of different Protein 
Chips allows the separation/targeting of proteins in the sam-
ple, thereby reducing the complexity of the sample [19, 21]. 
As a result of surface affinity capture, compounds with 
shared physical and chemical properties are retained; thus, 
the various analytes are likely to have a more equal probabil-
ity of becoming incorporated into the matrix crystal, which 
in turn reduces analyte signal suppression [18], the washing 
step removes most of the salts, which otherwise interfere 
with mass spectrometric analysis [21]. Finally, binding to the 
active probe surface may reveal the biomechanical property 
of the analyte, including chemical properties such as hy-
dropathicity, total charge, pI, phosphorylation, glycosylation, 
and primary composition [17].  
  There are however a few drawbacks of SELDI-TOF. 
First, high-molecular weight salivary proteins and glycopro-
teins such as mucins might not be detected [10,18,21]. How-
ever, more mass peaks in the high-molecular weight range 
may be obtained by applying more appropriate buffers or 
varying the stringency of the washing steps. Second, com-
petitive binding of high abundance non-informative proteins 
(like the mucins) on the chip surface may reduce the inten-
sity of peptides/proteins of interest, particularly the low 
abundance ones [21]. This can be overcome by pre-
fractionation of the saliva sample or the use of membranes 
with a specific cut-off. There is also concern that the protein 
peaks identified by SELDI-TOF and used for discriminating 
between cancer and control are not derived from the tumor 
per se but rather from the body's response to the cancer 
(epiphenomena) and that they may not be specific for cancer. 
Inflammatory conditions and benign pathologies may elicit 
the same bodily responses [4]. Finally, SELDI-TOF has low-
mass resolution, which together with a lack of tandem mass 
spectrometric capabilities, limits the identification of sali-
vary proteins [21]. In terms of reproducibility of the proce-
dure, investigators routinely incorporate a number of ap-
proaches to ensure reproducible results. These include add-
ing a quality control sample on each chip array, and normal-
izing spectral data through commercially available or in-
house generated computer programs [10, 19-21].  
SELDI-TOF APPLICATIONS FOR SALIVARY   
PROTEOMIC STUDIES 
  The application of SELDI TOF-MS technology is not 
limited to studies of ovarian [22], breast [23], pancreatic [24] 
and prostate cancers [25]. It has also been used in obtaining 
proteomic patterns for the diagnosis of bladder cancer from 
urine samples
  [26] and cervical cancer from laser capture 
microdissected captured cell lysates from tissue samples 
[27]. Cerebrospinal fluid (CSF) was used in finding and 
monitoring biomarkers for Alzheimer’s disease [20, 28].
 
  The proteins present in whole saliva are derived mainly 
from the salivary glands. Some proteins, however, originate 
from oral microorganisms, epithelial cells, crevicular fluid, 
leucocytes or dietary components. The relative contribution 
of sources other than the salivary glands to the composition 
of saliva will vary depending on e.g., the physiological status, 
method of stimulation, and the type of protein [10, 19, 20]. 
For decades, dental health professionals have used saliva to 
help assess the risk of caries by measuring its buffering ca-
pacity and bacterial content. Now, saliva is increasingly be-
ing used as an investigational aid in the diagnosis of human 
oral and systemic disease [7, 11, 12]. Such as Sjögren’s syn-
drome [29], cystic fibrosis [30], sarcoidosis [31], diabetes 
mellitus [32] and diseases of the adrenal cortex [33]. How-
ever, unlike the SELDI-TOF analyses of plasma/serum or 
CSF, salivary proteomics using SELDI-TOF is still in its 
infantile stage. There are only handful published articles on 
salivary proteomic analysis using SELDI-TOF (Table 1). 
Most of these studies are to improve the technology and not 
biomarker monitoring or discovery studies. 
  The usefulness of saliva determinations by SELDI-TOF 
mass spectrometry depends on the application of pre-
analytical procedures adequate for the assay in saliva. Once 
the saliva sample is collected, it is important that the han-
dling procedures do not affect the nature and the content of 
the saliva [10, 19, 21]. Most workers centrifuge the sample 
at 1000g, while others recommend higher centrifugation 
speed to remove cellular debris, bacteria and high molecular 
weight mucoproteins. Another point where opinions differ is 
the temperature to store samples if analysis is not performed 
immediately after sampling. In addition, slow freezing, long 
storage time, as well as freeze–thawing cycles may cause 
problems since some protein-induced precipitation may oc-
cur [10, 19, 21]. 
  Currently, there are four examples of human salivary 
proteomic studies using SELDI-TOF mass spectrometry to 
monitor known biomarkers or define novel biomarkers   
(Table 1). Two studies used SELDI-TOF in biomarker dis-
covery. Streckfus et al. proposed the use of SELDI-TOF 
analysis of saliva in breast cancer biomarker discovery [35]. 
Ryu et al. studied the salivary protein expression profiling in 
Sjgren’s syndrome [29]. Another two studies used SELDI-
TOF to monitor known biomarkers [34, 36].
 Imanguli et al. 
examined salivary proteomic profiles before and after stem 
cell therapy [34], and Kuwata et al. used SELDI-TOF analy-
sis to examine the presence of bacterial lactofericin in saliva 
[36].
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CONCLUSION 
  SELDI-TOF mass spectrometry combines the precision 
of MALDI-TOF proteomic analysis of mass spectrometry 
and the high-through-put nature of the protein array, Protein 
Chips. Despite this significant advancement and simplicity 
of the use of human saliva, there is only a handful clinic 
studies using SELDI-TOF in defining salivary proteome. 
This promising technology can be used to monitor known 
biomarkers and in novel biomarker discovery. SELDI-TOF 
can also be used as a tool to monitor the progress of diseases 
and effects of particular treatments.  
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